SummaryThe TGA says it cannot rule out reduced effectiveness of oral contraceptives when starting or increasing tirzepatide and advises using non-oral or barrier contraception for four weeks during those times. It also reviewed concerns about suicidal thoughts linked to GLP-1 drugs, finding no clear evidence but calling for consistent safety information.